Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Deferoxamine
Generic Name
Deferoxamine Mesylate
Active Ingredient
DeferoxamineCategory
Other
Salt Form
Mesylate
Variants
2
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Deferoxamine, you must consult a qualified healthcare professional.
Detailed information about Deferoxamine
Deferoxamine is a potent iron-chelating agent used to treat acute iron poisoning and chronic iron overload caused by frequent blood transfusions. It works by binding to free iron in the blood and facilitating its excretion through the kidneys and bile.
Dosage for deferoxamine is highly individualized based on the severity of iron overload and the patient's response to therapy.
Deferoxamine is approved for use in children, but dosing must be calculated with extreme precision to avoid growth retardation.
Because the ferrioxamine complex is primarily excreted through the kidneys, patients with pre-existing renal disease or kidney failure require significant dose reductions. In cases of anuria (no urine production), deferoxamine may only be used if the patient is undergoing dialysis to remove the chelated complex.
While the liver is not the primary site of metabolism, iron overload itself often causes liver damage. No specific dose adjustments are typically required for hepatic impairment, but close monitoring of liver enzymes is recommended.
Clinical studies did not include sufficient numbers of subjects aged 65 and over to determine if they respond differently. However, because elderly patients are more likely to have decreased renal function, dose selection should be cautious, usually starting at the lower end of the dosing range.
If a dose is missed, it should be administered as soon as possible. However, if it is almost time for the next scheduled infusion, skip the missed dose and return to the regular schedule. Do not double the dose to 'catch up,' as this increases the risk of toxicity to the eyes and ears.
Signs of an acute overdose of deferoxamine include severe low blood pressure (hypotension), rapid heart rate (tachycardia), gastrointestinal upset, and temporary vision or hearing loss. In the event of a suspected overdose, the infusion must be stopped immediately, and emergency medical services should be contacted. Treatment is supportive, focusing on maintaining blood pressure and heart function.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or stop the medication without medical guidance, as iron levels can rise rapidly and cause organ damage.
Most patients receiving deferoxamine will experience some level of side effects, particularly related to the method of administration.
Deferoxamine is a high-alert medication that requires diligent monitoring by both the patient and the medical team. It is not a 'set and forget' treatment. Because it affects the body's mineral balance and can impact sensory organs, patients must adhere to all scheduled laboratory and diagnostic appointments.
No FDA black box warnings for Deferoxamine. While it lacks a boxed warning, the risk of fatal infections and permanent sensory loss necessitates strict clinical oversight.
Deferoxamine is known to cause dose-related toxicity to the optic nerve and the auditory system. Patients have reported night blindness, visual field defects, and high-frequency hearing loss. These risks are significantly higher when the dose exceeds 50 mg/kg/day or when iron levels (ferritin) are low. Baseline ophthalmological and audiometric testing must be performed before starting therapy and repeated every 6 to 12 months.
There are few absolute contraindications for drug combinations, but the following require extreme caution:
Vitamin C increases the availability of iron for chelation, which can make deferoxamine more effective. However, in the early stages of treatment, excess Vitamin C can mobilize too much iron, leading to increased oxidative stress on the heart. This can result in acute cardiac failure.
Deferoxamine must NEVER be used in the following circumstances:
These conditions require a careful risk-benefit analysis by the healthcare provider:
Deferoxamine is classified as Pregnancy Category C. Animal studies have demonstrated that the drug can cause skeletal abnormalities in the offspring when administered at doses similar to human doses. There are no adequate, well-controlled studies in pregnant women.
It is not known whether deferoxamine is excreted in human milk. Because many drugs are excreted in breast milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Deferoxamine is a trihydroxamic acid that functions as a high-affinity chelator. Its molecular structure allows it to form a stable, hexadentate complex with ferric iron (Fe3+). It essentially 'cages' the iron atom, preventing it from participating in the Fenton reaction—a chemical process that generates highly reactive hydroxyl radicals. By neutralizing these radicals, deferoxamine protects cellular membranes, proteins, and DNA from oxidative damage. It does not effectively remove iron from hemoglobin or cytochromes, which is vital for maintaining normal oxygen transport and cellular respiration.
The relationship between the dose of deferoxamine and the amount of iron excreted is roughly linear within the therapeutic range. The onset of iron excretion begins within hours of starting an infusion and peaks toward the end of the infusion period. The duration of effect is short, which is why long infusions (8-12 hours) are more effective than rapid injections for chronic overload; they ensure the drug is present as iron is slowly released from storage sites.
| Parameter | Value |
Common questions about Deferoxamine
Deferoxamine is primarily used to treat two conditions related to excess iron: acute iron poisoning and chronic iron overload. Acute poisoning often occurs in children who accidentally swallow iron supplements, while chronic overload happens in patients who receive many blood transfusions for diseases like thalassemia or sickle cell anemia. The drug works by binding to the extra iron in the body and helping the kidneys flush it out through the urine. In some cases, it is also used to remove excess aluminum in patients on long-term kidney dialysis. It is considered a life-saving medication for those with severe metal toxicity.
The most common side effects are local reactions at the injection site, such as pain, swelling, redness, and itching. Many patients also notice that their urine turns a reddish-orange color, which is a normal sign that the drug is working to remove iron. Other frequent side effects include fever, nausea, and muscle or joint aches. Some people may also experience a mild skin rash or hives. While these are usually not dangerous, they should be reported to a healthcare provider if they become bothersome.
While there is no known direct chemical interaction between Deferoxamine and alcohol, drinking is generally discouraged for patients requiring this medication. Most people taking Deferoxamine have iron overload, which can cause significant damage to the liver, such as cirrhosis or scarring. Alcohol also stresses the liver and can accelerate this damage, making the overall health situation worse. It is best to discuss your alcohol consumption with your hematologist to understand your specific risks. If you do choose to drink, it should be in very limited moderation.
Deferoxamine is generally not recommended during pregnancy, especially during the first trimester, because animal studies have shown it can cause bone abnormalities in the fetus. It is classified as Pregnancy Category C, meaning the risks are not fully known in humans but potential harm exists. Doctors will only prescribe it to a pregnant woman if the benefit of treating life-threatening iron poisoning outweighs the risk to the baby. If you are planning to become pregnant or find out you are pregnant while on this drug, notify your doctor immediately. Alternative treatments or a temporary pause in therapy may be necessary.
In the case of acute iron poisoning, Deferoxamine begins to bind iron almost immediately after the intravenous infusion starts, and you may see the effects in your urine within an hour. For chronic iron overload, the process is much slower and requires long-term commitment. It may take several months of daily or near-daily infusions to see a significant drop in your body's total iron stores (ferritin levels). Consistency is key, as the drug only removes a small amount of iron during each 8-to-12-hour session. Your doctor will monitor your progress with regular blood tests.
You should never stop taking Deferoxamine suddenly without consulting your healthcare provider. While stopping the drug does not cause immediate withdrawal symptoms like some other medications, it allows iron to begin building up in your organs again right away. For patients with severe iron overload, this can lead to a dangerous accumulation of iron in the heart, potentially causing heart failure or arrhythmias. If you are having trouble with the daily infusions, talk to your doctor about other options, such as oral chelators. A safe transition plan is essential to protect your heart and liver.
If you miss a dose of Deferoxamine, you should take it as soon as you remember that same day. However, if it is nearly time for your next scheduled dose, it is better to skip the missed dose and stay on your regular schedule. Do not double the dose or run the pump for twice as long to make up for the missed time, as this can increase the risk of toxicity to your eyes and ears. Keeping a consistent schedule is important for effective iron removal. If you find yourself missing doses frequently, discuss using a reminder app or a different treatment schedule with your nurse.
Weight gain is not a recognized side effect of Deferoxamine. In fact, some patients may experience a slight loss of appetite or nausea, which could lead to weight loss. If you notice significant or rapid weight gain while taking this medication, it may be a sign of a different problem, such as fluid retention related to heart or kidney issues—both of which can be complications of iron overload itself. You should report any sudden changes in weight or swelling in your ankles to your doctor. They will evaluate whether the change is related to the medication or your underlying condition.
Deferoxamine can interact with several other drugs, so it is vital to provide your doctor with a full list of your medications. A very important interaction is with Vitamin C; while it can help the drug work better, taking it incorrectly can cause heart problems. You should also avoid certain nausea medications like prochlorperazine, which can cause a loss of consciousness when combined with Deferoxamine. Most other common medications for blood pressure or infection are safe, but your pharmacist should always check for compatibility. Always inform any new doctor that you are on iron chelation therapy.
Yes, Deferoxamine mesylate is available as a generic medication and is also sold under the brand name Desferal. The generic versions are required by the FDA to be 'bioequivalent' to the brand-name drug, meaning they have the same active ingredient and work the same way in the body. Generic versions are typically more cost-effective for patients and hospitals. Regardless of whether you use the brand or the generic, the medication must be reconstituted and administered the same way. Check with your insurance provider to see which version is covered under your plan.
Other drugs with the same active ingredient (Deferoxamine)
> Warning: Stop taking Deferoxamine and call your doctor immediately if you experience any of these serious symptoms.
No FDA black box warnings are currently issued for Deferoxamine. However, the drug carries significant 'Precautions' regarding sensory (vision/hearing) loss and infection risks that are treated with the same level of clinical seriousness as a boxed warning.
Report any unusual symptoms, especially changes in your vision or hearing, to your healthcare provider immediately. Regular screening (every 6-12 months) is the standard of care for long-term users.
Iron-chelating agents can predispose patients to specific infections. Yersinia enterocolitica and Yersinia pseudotuberculosis are 'siderophilic' (iron-loving) bacteria. Deferoxamine can facilitate the growth of these bacteria, leading to sepsis. If a patient develops a fever or enteritis (bowel inflammation), treatment should be suspended until the infection is cleared. Furthermore, rare cases of Mucormycosis (a deadly fungal infection) have been reported.
Rapid intravenous administration can cause a sudden release of histamine, leading to flushing, urticaria, and profound hypotension (low blood pressure), which can progress to shock. IV infusions must be administered slowly.
High doses of IV deferoxamine (usually exceeding 10-15 mg/kg/hour) have been associated with Acute Respiratory Distress Syndrome (ARDS). Patients receiving intensive IV chelation must be monitored for sudden onset of cough or breathlessness.
To ensure safety, the following tests are typically required:
Deferoxamine may cause dizziness or visual disturbances (such as blurred vision). Patients should not drive or operate heavy machinery until they are certain the medication does not impair their ability to do so safely.
There is no direct chemical interaction between alcohol and deferoxamine. However, chronic iron overload often causes liver damage (cirrhosis). Alcohol consumption can worsen liver injury and is generally discouraged in patients with hemosiderosis.
Stopping deferoxamine suddenly does not cause a withdrawal syndrome. However, it will cause iron levels to begin rising immediately. In patients with severe iron overload, stopping treatment can lead to rapid cardiac iron deposition and heart failure. Never stop treatment without a transition plan from your doctor.
> Important: Discuss all your medical conditions, especially any history of kidney disease or vision problems, with your healthcare provider before starting Deferoxamine.
Deferoxamine binds to Gallium-67, a radioactive tracer used in certain medical scans (scintigraphy). This leads to rapid excretion of the tracer and can make the scan results uninterpretable.
While deferoxamine is used to treat aluminum toxicity, taking oral aluminum-containing antacids can interfere with the overall balance of metal chelation in the body. Discuss the use of antacids with your hematologist.
Because deferoxamine is administered by injection, food does not affect its absorption. However, diet plays a role in iron management:
Deferoxamine can interfere with certain laboratory measurements:
For each major interaction, the primary mechanism is either direct chemical binding (chelation) or a pharmacodynamic effect (like Vitamin C's effect on iron mobilization). The clinical consequence is usually either increased organ toxicity or reduced diagnostic accuracy.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter Vitamin C.
There are no closely related drugs to deferoxamine that commonly cause cross-sensitivity. However, patients should be aware that the 'mesylate' salt is also used in other medications; while an allergy to the salt itself is rare, it is a theoretical consideration for those with multiple drug allergies.
> Important: Your healthcare provider will evaluate your complete medical history, including kidney function and sensory health, before prescribing Deferoxamine.
Deferoxamine is used extensively in children with transfusion-dependent thalassemia. However, it must be used with caution:
Elderly patients may be more susceptible to the side effects of deferoxamine, particularly the risk of hearing loss and kidney strain. Because kidney function naturally declines with age, the dose must be carefully adjusted based on the calculated glomerular filtration rate (GFR). Polypharmacy (taking many medications) in the elderly also increases the risk of the prochlorperazine interaction.
In patients with mild to moderate renal impairment, the dose should be reduced, and kidney function should be monitored every few weeks. In end-stage renal disease (ESRD), deferoxamine can only be used if the ferrioxamine complex is removed via hemodialysis or peritoneal dialysis.
No specific dose adjustments are provided in the manufacturer's labeling for hepatic impairment. However, since the liver is a primary site of iron storage and damage, liver function tests should be monitored to ensure the drug is effectively reducing the iron burden without causing further stress to the organ.
> Important: Special populations require individualized medical assessment and more frequent monitoring of drug levels and side effects.
| Bioavailability | <15% (Oral), 100% (IM/SC) |
| Protein Binding | <10% |
| Half-life | 20 - 30 minutes (Parent drug) |
| Tmax | 30 minutes (after IM injection) |
| Metabolism | Plasma enzymes (hydrolysis/oxidation) |
| Excretion | Renal (Urine) and Biliary (Feces) |
Deferoxamine is the prototypical member of the iron-chelating agent class. While newer oral agents like Deferasirox and Deferiprone have been developed, Deferoxamine remains the most potent and reliable option for rapid iron removal in acute settings and for patients who do not tolerate oral therapy.